Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sikarin PCLBKK:SKR-R -0.63%90 EV-to-EBITDA is 10.80 as of Aug. 26, 2026, which is 21% below its 10-year median of 13.72. GuruFocus rates BKK:SKR-R with a GF Score™ of 90/100 and a GF Value™ of ฿8.11 (Fairly Valued). The stock has 5 warning signs investors should review. Among 517 Healthcare Providers & Services companies, Sikarin PCL ranks worse than 50.87% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sikarin PCL's enterprise value is ฿15,106 Mil.
Sikarin PCL's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ฿1,398 Mil. Therefore, Sikarin PCL's EV-to-EBITDA for today is 10.80.
The historical rank and industry rank for Sikarin PCL's EV-to-EBITDA or its related term are showing as below:
BKK:SKR-R'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.17 Med: 13.72 Max: 24.16
Current: 10.8
During the past 13 years, the highest EV-to-EBITDA of Sikarin PCL was 24.16. The lowest was 8.17. And the median was 13.72.
BKK:SKR-R's EV-to-EBITDA is ranked worse than 50.87% of 517
companies
in the Healthcare Providers & Services industry
Industry Median: 10.63
vs BKK:SKR-R: 10.80
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sikarin PCL's PE Ratio (TTM) for today is calculated as:
Sikarin PCL's share price for today is ฿7.85.
Sikarin PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0.304.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Sikarin PCL's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:SKR-R vs HCA, THC, DVA: EV-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Sikarin PCL's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sikarin PCL EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sikarin PCL's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sikarin PCL's EV-to-EBITDA falls into.
Sikarin PCL's current Enterprise Value is ฿15,106 Mil.
Sikarin PCL's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿1,398 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sikarin PCL (BKK:SKR-R) has a EV-to-EBITDA of 10.80 as of Aug. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sikarin PCL. This is 21% below median its historical median of 13.72. Over the past decade, Sikarin PCL's EV-to-EBITDA has ranged from 8.17 to 24.16. According to the industry distribution chart, Sikarin PCL ranks #263 out of 517 companies in the Healthcare Providers & Services industry, placing it in the top 50.9%.
Is Sikarin PCL's EV-to-EBITDA too high?
Sikarin PCL's current EV-to-EBITDA of 10.80 is 21% below median its 10-year median of 13.72. Over the past 10 years, this metric has ranged from a low of 8.17 to a high of 24.16. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.63. Sikarin PCL's value of 10.80 is 1.6% above this industry median. Based on the distribution chart, Sikarin PCL ranks #263 out of 517 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Sikarin PCL has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sikarin PCL's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Sikarin PCL ranks #263 out of 517 companies for EV-to-EBITDA. This places Sikarin PCL in the lower half of its industry. The industry median EV-to-EBITDA is 10.63. Sikarin PCL's value of 10.80 is 1.6% above this benchmark. Historically, Sikarin PCL's own EV-to-EBITDA has ranged from 8.17 to 24.16 over the past decade. While the company's 10-year median is 13.72 vs. the industry median of 10.63, Sikarin PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.63, based on 517 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sikarin PCL's current EV-to-EBITDA of 10.80 is 1.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sikarin PCL. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sikarin PCL's current EV-to-EBITDA is 10.80, which is 21% below median its own 10-year median of 13.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sikarin PCL stock overvalued right now?
Based on GuruFocus' analysis, Sikarin PCL (BKK:SKR-R) is currently considered Fairly Valued. The stock's GF Value™ is ฿8.11, compared to a current price of ฿7.85 — trading 3.2% below its estimated fair value. The current EV-to-EBITDA is 10.80, which is 21% below median its 10-year median of 13.72 and 1.6% above the Healthcare Providers & Services industry median of 10.63. Sikarin PCL's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sikarin PCL (BKK:SKR-R), the current EV-to-EBITDA is 10.80 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sikarin PCL (BKK:SKR-R) Overvalued in 2026?
Based on GuruFocus' analysis, Sikarin PCL stock appears to be undervalued.
The current stock price of ฿7.85 is trading 3.2% below its estimated GF Value™ of ฿8.11.
GuruFocus considers Sikarin PCL to be Fairly Valued.
Key valuation signals for BKK:SKR-R:
EV-to-EBITDA: 10.80 (21% below median its 10-year median of 13.72)
GF Value™: ฿8.11 vs. price of ฿7.85 (3.2% below fair value)
Industry Position: 1.6% above the Healthcare Providers & Services median (#263 of 517)
No single metric tells the full story. See the BKK:SKR-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSikarin PCL provides general healthcare services and operates under the social security system. The Group has one main operating segment, which is providing healthcare services through private hospitals and hospitals affiliated with the social security system. The Group operates in a single geographical area, which is Thailand. Its services include medical centers, a pediatric center, a women's institute, a radiology center, a neurology center, a rehabilitation center, and an orthopedic center.
90GF Score
Get the complete analysis for BKK:SKR-R
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:SKR-R has been successfully added to your 
